Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920773 | 0.91 | MAP2K1 (0.45) | MAP2K1CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL12533986 | 0.86 | MAP2K1 (0.57) | MAP2K1CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL2563419 | 0.84 | MAP2K1 (0.68) | MAP2K1CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL1218846 | 0.84 | MAP2K1 (0.48) | MAP2K1CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL14199457 | 0.83 | MAP2K1 (0.59) | MAP2K1CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL1218790 | 0.83 | MAP2K1 (0.46) | MAP2K1CYP2C9CYP2C19KCNH2MEN1 | |
| SCHEMBL2023262 | 0.83 | MAP2K1 (0.51) | MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL2024343 | 0.83 | MAP2K1 (0.51) | MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL2023048 | 0.83 | MAP2K1 (0.51) | MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL13062517 | 0.82 | MAP2K1 (0.57) | MAP2K1CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | MAP2K1 24/4885CYP2C9 2527/4885CYP2C19 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.